Stock Ratings / Health Care / IBO / news

ACET (36) IXHL (39) FLNA (47) AARD (37) ⌘ Pro Terminal →

Why IBO Stock dropped -3.00% Today — RQD Quant Desk Flash

$3.87 -3.00% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot)

Impact BioMedical Inc. (IBO) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $33.1M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • E

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-10.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for IBO)Realized 20D OHLCV Swing Band: ±12.5%

AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →

Why IBO Stock dropped -3.00% Today — RQD Quant Desk Flash

Impact BioMedical Inc. (IBO) dropped -3.00% to $3.87, trading at 18% of its 52-week range ($2.43 – $10.51). Stretched risk/reward at current multiples (-28% return on capital) under elevated 10-year interest-rate pressure.

▸Technical Tape: Trading at 18% of its 52-week range ($2.43 – $10.51) with RSI-14 at 43.4 (NEUTRAL RANGE).
▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $3.87 (no active unusual options sweep snapshot on file).
▸Fundamental Anchor: Roarable E (Strong Sell) backed by 0% gross margin and $0 annual free cash flow.

Live IBO Headlines & Catalysts

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring IBO)

✓Walkthrough of IBO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

IBO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -55.05%📐 HORIZONTAL RANGE

2026-10-30O $3.52H $4.10L $3.52C $3.87VOL 15.3K

RES: $8.26SUP: $2.03SMA50: $5.17SMA200: $6.28

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

IBO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 IBO Butterfly Map → + Track IBO →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on IBO today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for IBO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for IBO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (IBO)

Health Care Rank #851 of 1016 ⚔️ ACET vs IBO Full Matrix →

1. Head-to-Head Health Care Peer Comparison (IBO vs. ACET, IXHL, FLNA, AARD)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Impact BioMedical Inc. (IBO) ranks #851 by composite RQD confidence (34/100, grade E) and #792 by equity capitalization ($33.1M). Within this direct 5-issuer industry benchmark cohort, IBO leads on earnings valuation at N/A trailing P/E, while IBO leads on capital efficiency and profitability with -27.5% ROIC and -30.0% gross margin. FLNA currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with IBO at 34/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
IBO ACTIVE Impact BioMedical Inc.	E	34/100	—	-30.0%	-27.5%	-3.00%	$33.1M	Benchmark Subject
ACET Adicet Bio Inc.	D-	36/100	—	—	-35.0%	-6.04%	$33.5M	/acet-vs-ibo →
IXHL Incannex Healthcare Inc.	D-	39/100	—	—	-35.0%	-4.80%	$32.4M	/ixhl-vs-ibo →
FLNA Filana Therapeutics Inc.	D	47/100	—	—	-35.0%	+1.12%	$31.8M	/flna-vs-ibo →
AARD Aardvark Therapeutics Inc.	D-	37/100	—	—	-35.0%	-4.64%	$31.5M	/aard-vs-ibo →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001834105

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Impact BioMedical Inc. (IBO) reported GAAP revenue of $32.0K (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$11.8M, operating cash flow of -$1.9M, and free cash flow of -$1.9M (+33.8% YoY). On the balance sheet, IBO closed FY2025 with $17.4M in total assets against $0 in total debt (Altman Z-Score: 5.88, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$32.0K	-$11.8M	-$1.9M	-$1.9M	$17.4M	—
FY2024 (FY)	2024-12-31	$0	-$24.7M	-$2.9M	-$2.9M	$20.3M	—
FY2023 (FY)	2023-12-31	$0	-$4.3M	-$2.9M	-$2.9M	—	—

3. IBO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is IBO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Impact BioMedical Inc. (NYSE: IBO) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $3.87 (-3.00% 1D, market cap $33.1M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, IBO ranks #851 in composite RQD confidence.

How does IBO compare to ACET and IXHL in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), IBO carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of -30.0%, and ROIC of -27.5%. By comparison, ACET (Adicet Bio Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $33.5M) and IXHL (Incannex Healthcare Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $32.4M). Among the 5-stock peer group, IBO leads on earnings multiple (N/A) while IBO leads on capital efficiency (-27.5% ROIC).

What are the biggest fundamental strengths and SEC risk factors for IBO?

Per IBO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001834105), Impact BioMedical Inc. generated $32.0K in revenue, -$11.8M in net income, and -$1.9M in free cash flow against $17.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is IBO trading relative to its 50-day, 200-day, and 52-week technical levels?

IBO last traded at $3.87 (-3.00% on volume of 23,867 shares), positioning the stock -25.15% below its 50-day simple moving average ($5.17) and -38.38% below its 200-day simple moving average ($6.28). Across its 52-week range of $2.43 to $10.51, IBO sits at the 17.8% percentile with a 14-day RSI of 43.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.39 to $4.35).

IBO Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Why is IBO stock moving today?

Why IBO Stock dropped -3.00% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-28% return on capital) under elevated 10-year interest-rate pressure.

Direct Sub-Reports: IBO RQD Cockpit IBO 12M Forecast IBO Earnings & Move IBO Dividends & DRIP IBO Insiders & 13F IBO Whale Options IBO Profit Sankey IBO News & Why